Cover Image
Market Research Report

Market Spotlight: Uterine Cancer

Published by Datamonitor Healthcare Product code 603896
Published Content info 45 Pages
Delivery time: 1-2 business days
Price
Back to Top
Market Spotlight: Uterine Cancer
Published: December 4, 2019 Content info: 45 Pages
Description

This Market Spotlight report covers the uterine cancer market, comprising key pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, recent events and analyst opinion, key upcoming events, probability of success, and licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were 377,900 incident cases of uterine cancer in females aged 15 years and over worldwide, and expects that number to increase to 413,600 incident cases by

2026. In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by

2026. Merck's Keytruda and Eisai's Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes.

The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with two drugs in Phase III.

Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.

The only high-impact upcoming event in the uterine cancer space is the release of topline Phase II trial results for XBIO-101. The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 41%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been nine licensing and asset acquisition deals involving endometrial cancer drugs during 2014-19. The $1,657m collaboration and exclusive license agreement signed in 2014 between AnaptysBio and Tesaro, pursuant to which Tesaro was granted exclusive rights to antibody programs targeting PD-1, TIM-3, and LAG-3, including monospecific and dual reactive antibody drug candidates, was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 94% of trials in Phase I-II, and only 6% in Phase III-IV.

The US has a substantial lead in the number of uterine neoplasms clinical trials globally, while Spain and the UK lead the major EU markets.

Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.

AstraZeneca leads the industry sponsors with the highest number of overall clinical trials for uterine neoplasms

Table of Contents
Product Code: DMKC0183133

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

9 TREATMENT

9 Surgery

9 Radiation therapy

9 Chemotherapy

10 Hormone therapy

10 Palliative care

11 EPIDEMIOLOGY

15 MARKETED DRUGS

17 PIPELINE DRUGS

24 RECENT EVENTS AND ANALYST OPINION

24 MGA012 for Uterine Cancer (July 2, 2019)

25 Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)

25 TAK-117 for Uterine Cancer (March 20, 2019)

26 Dostarlimab for Uterine Cancer (March 19, 2019)

28 DKN-01 for Uterine Cancer (March 18, 2019)

29 Dostarlimab for Uterine Cancer (October 20, 2018)

31 Keytruda for Uterine Cancer (June 3, 2018)

33 KEY UPCOMING EVENTS

34 KEY REGULATORY EVENTS

34 FDA Issues Pair Of RTOR Approvals To Keytruda/Lenvima Combo, Erleada

34 Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

35 PROBABILITY OF SUCCESS

36 LICENSING AND ASSET ACQUISITION DEALS

36 Deals Shaping The Medical Industry, August 2019

37 PARENT PATENTS

38 REVENUE OPPORTUNITY

39 CLINICAL TRIAL LANDSCAPE

40 Sponsors by status

41 Sponsors by phase

43 BIBLIOGRAPHY

43 Prescription Information

44 APPENDIX

LIST OF FIGURES

  • 13 Figure 1: Trends in incident cases of uterine cancer, 2017-26
  • 17 Figure 2: Overview of pipeline drugs for uterine cancer in the US
  • 18 Figure 3: Pipeline drugs for uterine cancer, by company
  • 18 Figure 4: Pipeline drugs for uterine cancer, by drug type
  • 18 Figure 5: Pipeline drugs for uterine cancer, by classification
  • 28 Figure 6: Dostarlimab for Uterine Cancer (March 19, 2019): Phase I - GARNET
  • 29 Figure 7: DKN-01 for Uterine Cancer (March 18, 2019): Phase II - Gynecologic Malignancies (P204)
  • 31 Figure 8: Dostarlimab for Uterine Cancer (October 20, 2018): Phase I - GARNET
  • 32 Figure 9: Keytruda for Uterine Cancer (June 3, 2018): Phase I/II - KEYNOTE-146 (w/Lenvima)
  • 33 Figure 10: Key upcoming events in uterine cancer
  • 35 Figure 11: Probability of success in the uterine cancer pipeline
  • 36 Figure 12: Licensing and asset acquisition deals in uterine cancer, 2014-19
  • 37 Figure 13: Parent patents in uterine cancer
  • 39 Figure 14: Clinical trials in uterine cancer
  • 39 Figure 15: Top 10 drugs for clinical trials in uterine cancer
  • 40 Figure 16: Top 10 companies for clinical trials in uterine cancer
  • 40 Figure 17: Trial locations in uterine cancer
  • 41 Figure 18: Uterine cancer trials status
  • 42 Figure 19: Uterine cancer trials sponsors by phase

LIST OF TABLES

  • 12 Table 1: Incident cases of uterine cancer, 2017-26
  • 14 Table 2: Five-year prevalent cases of uterine cancer, 2017-26
  • 16 Table 3: Marketed drugs for uterine cancer
  • 20 Table 4: Pipeline drugs for uterine cancer in the US
  • 24 Table 5: MGA012 for Uterine Cancer (July 2, 2019)
  • 25 Table 6: Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)
  • 26 Table 7: TAK-117 for Uterine Cancer (March 20, 2019)
  • 27 Table 8: Dostarlimab for Uterine Cancer (March 19, 2019)
  • 28 Table 9: DKN-01 for Uterine Cancer (March 18, 2019)
  • 30 Table 10: Dostarlimab for Uterine Cancer (October 20, 2018)
  • 31 Table 11: Keytruda for Uterine Cancer (June 3, 2018)
  • 38 Table 12: Historical global sales, by drug ($m), 2014-18
  • 38 Table 13: Forecasted global sales, by drug ($m), 2019-23
Back to Top